The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

Beyfortus (nirsevimab) has also been approved in the US and Canada, EU, and GB, and is under review in other countries, including Japan, as a one-dose preventative treatment to protect infants ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...

The pioneering beyfortus provides a solution to decrease RSV cases. It bolsters passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the ...